Three Undiscovered Gems In India To Enhance Your Portfolio

In This Article:

In the last week, the Indian market has stayed flat, yet it is up 44% over the past year with earnings expected to grow by 17% per annum over the next few years. In such a dynamic environment, identifying stocks with strong growth potential and solid fundamentals can be key to enhancing your portfolio.

Top 10 Undiscovered Gems With Strong Fundamentals In India

Name

Debt To Equity

Revenue Growth

Earnings Growth

Health Rating

Shree Digvijay Cement

0.01%

13.97%

16.37%

★★★★★★

Vidhi Specialty Food Ingredients

7.27%

11.00%

4.02%

★★★★★★

Aeroflex Industries

0.04%

14.69%

33.38%

★★★★★★

Knowledge Marine & Engineering Works

35.48%

46.55%

46.96%

★★★★★★

Bengal & Assam

4.48%

1.54%

51.11%

★★★★★☆

Voith Paper Fabrics India

0.07%

10.95%

9.70%

★★★★★☆

Gallantt Ispat

18.85%

37.56%

37.26%

★★★★★☆

Piccadily Agro Industries

50.57%

13.86%

42.85%

★★★★★☆

Insolation Energy

88.64%

163.87%

419.31%

★★★★★☆

Sanstar

50.30%

-8.41%

48.59%

★★★★☆☆

Click here to see the full list of 460 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.

We're going to check out a few of the best picks from our screener tool.

IIFL Securities

Simply Wall St Value Rating: ★★★★☆☆

Overview: IIFL Securities Limited offers capital market services in India's primary and secondary markets, with a market cap of ?68.43 billion.

Operations: IIFL Securities Limited generates revenue primarily from capital market activities (?20.25 billion), with additional income from facilities and ancillary services (?375.25 million) and insurance broking and ancillary services (?2.77 billion).

IIFL Securities, a notable player in India's financial sector, has shown impressive earnings growth of 120.4% over the past year, outpacing the industry average of 64%. The company's price-to-earnings ratio stands at an attractive 12.4x compared to the Indian market's 32.9x. Despite recent volatility in share price and a penalty from SEBI for technical errors, IIFLSEC's net debt to equity ratio is satisfactory at 35.5%, and its high-quality earnings underscore its potential as an investment gem.

NSEI:IIFLSEC Debt to Equity as at Aug 2024

Marksans Pharma

Simply Wall St Value Rating: ★★★★★★

Overview: Marksans Pharma Limited, along with its subsidiaries, focuses on the research and development, manufacturing, marketing, and sale of generic pharmaceutical formulations globally and has a market cap of ?99.76 billion.

Operations: Marksans Pharma Limited generates revenue primarily from its pharmaceutical segment, which amounted to ?22.68 billion. The company has a market cap of ?99.76 billion.